Schroder Investment Management Group Boosts Stock Position in Ascendis Pharma A/S (NASDAQ:ASND)

Schroder Investment Management Group grew its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 14.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 92,728 shares of the biotechnology company's stock after purchasing an additional 11,739 shares during the period. Schroder Investment Management Group owned 0.15% of Ascendis Pharma A/S worth $12,656,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Groupama Asset Managment acquired a new stake in Ascendis Pharma A/S during the third quarter worth approximately $60,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Ascendis Pharma A/S during the 3rd quarter worth $19,908,000. Zimmer Partners LP acquired a new stake in shares of Ascendis Pharma A/S during the third quarter worth $11,646,000. American Century Companies Inc. grew its position in shares of Ascendis Pharma A/S by 17.5% in the fourth quarter. American Century Companies Inc. now owns 407,294 shares of the biotechnology company's stock valued at $56,072,000 after purchasing an additional 60,548 shares during the period. Finally, Artisan Partners Limited Partnership increased its stake in Ascendis Pharma A/S by 0.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 4,450,420 shares of the biotechnology company's stock valued at $612,689,000 after purchasing an additional 39,309 shares during the last quarter.

Ascendis Pharma A/S Price Performance

NASDAQ ASND traded down $2.73 on Tuesday, reaching $137.41. The company had a trading volume of 523,553 shares, compared to its average volume of 474,890. Ascendis Pharma A/S has a 1 year low of $111.09 and a 1 year high of $169.37. The firm has a 50-day moving average of $147.03 and a 200-day moving average of $137.74. The firm has a market capitalization of $8.34 billion, a PE ratio of -19.35 and a beta of 0.54.

Remove Ads

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($1.32) by $0.64. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. The Goldman Sachs Group lifted their price target on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Cantor Fitzgerald upped their price target on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 25th. Evercore ISI lifted their price target on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a report on Tuesday, February 18th. JPMorgan Chase & Co. upped their price objective on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a report on Tuesday, March 18th. Finally, Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a research report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S has a consensus rating of "Moderate Buy" and an average target price of $204.64.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.